Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer

Abouzeid, Abraham H.; Patel, Niravkumar R.; Torchilin, Vladimir P.

doi:10.1016/j.ijpharm.2014.01.009

Cited by 110 publications

(65 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In reported studies, there have been many examples of applying Cur in combination therapies. Abouzeid et al 57 codelivered Cur and paclitaxel, and they observed a clear synergistic effect against SKOV-3TR cells. Carlson et al 58 found that the combination of resveratrol and Cur were also synergistic in inhibiting SKOV3 cell proliferation.…”

mentioning

confidence: 99%

Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis

Zhou¹,

Duan²,

Zeng³

et al. 2015

IJN

View full text Add to dashboard Cite

Natural product curcumin (Cur) and H 2 S-releasing prodrug SH-aspirin (SH-ASA) are potential anticancer agents with diverse mechanisms, but their clinical application prospects are restricted by hydrophobicity and limited efficiency. In this work, we coencapsulated SH-ASA and Cur into methoxy poly(ethylene glycol)-poly (lactide-coglycolide) (mPEG-PLGA) nanoparticles through a modified oil-in-water single-emulsion solvent evaporation process. The prepared SH-ASA/Cur-coloaded mPEG-PLGA nanoparticles had a mean particle size of 122.3±6.8 nm and were monodispersed (polydispersity index =0.179±0.016) in water, with high drug-loading capacity and stability. Intriguingly, by treating with SH-ASA/Cur-coloaded mPEG-PLGA nanoparticles, obvious synergistic anticancer effects on ES-2 and SKOV3 human ovarian carcinoma cells were observed in vitro, and activation of the mitochondrial apoptosis pathway was indicated. Our results demonstrated that SH-ASA/Cur-coloaded mPEG-PLGA nanoparticles could have potential clinical advantages for the treatment of ovarian cancer.

show abstract

mentioning

confidence: 99%

Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis

Zhou¹,

Duan²,

Zeng³

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…It is well known that the interaction between hydrophobic drugs and the micelle core environment is a very important factor in micelle stability. 50 After reconstituting the lyophilized micelles in aqueous solutions in the present study, the hydrophobic segment of Figure 8 The appearances of DMc-PMs before lyophilization (A), lyophilized powder (B), and reconstituted solution (C). Abbreviation: DMc-PMs, dimethoxycurcumin-loaded polymeric micelles.…”

Section: In Vitro Stabilitymentioning

confidence: 82%

Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting

Liu¹,

Xu²,

Jiang³

et al. 2015

IJN

View full text Add to dashboard Cite

Dimethoxycurcumin (DMC) is an analog of curcumin with superior efficacy in various disease models. Currently, drug delivery system research on DMC is very limited, and it has become a huge challenge to realize further developments and clinical applications. In the present study, a kind of amphiphilic block copolymer, N- t -butoxycarbonyl-phenylalanine terminated monomethoxyl poly (ethylene glycol)-b-poly (ε-caprolactone), or mPEG-PCL-Phe(Boc), was prepared from monomethoxyl poly (ethylene glycol)-b-poly (ε-caprolactone) (mPEG-PCL) with its hydroxyl terminal chemically converted into N- t -butoxycarbonyl-phenylalanine (Boc-Phe). This copolymer was determined to have a fairly low critical micelle concentration (2.56×10 −3 mg/mL) and passive targeting potential to tumor tissue, and thus was applied to develop a polymeric micellar formulation of DMC for the first time. The DMC-loaded micelles prepared by thin-film hydration method had typical shell–core structure, with an average particle size of 17.9±0.4 nm and a polydispersity index of 0.045±0.011. The drug loading capacity and entrapment efficiency were 9.94%±0.15% and 97.22%±0.18%, respectively, indicating a high-affinity interaction between DMC and the copolymer. At a concentration of 2 mg/mL, the reconstituted micelle solution could be maintained for at least 10 days at room temperature, and displayed a low initial burst release followed by a sustained release in vitro. Pharmacokinetic study in rats revealed that in vivo drug exposure of DMC was significantly increased and prolonged by intravenously administering DMC-loaded micelles when compared with the same dose of free DMC dissolved in dimethyl sulfoxide. Furthermore, in vivo distribution results from tumor-bearing nude mice demonstrated that this micellar formulation significantly changed the biodistribution profile of DMC and increased drug accumulation in tumors. Therefore, the polymeric micellar formulation of DMC, based on the amphiphilic block copolymer, mPEG-PCL-Phe(Boc), could provide a desirable method for delivering DMC, especially for applications in cancer therapy.

show abstract

“…Cisplatin and paclitaxel PEG-PGlu90-PPhe25 hybrid micelles Ovarian cancer [56] Linear-dendritic telodendrimer micelles Ovarian cancer [57] Doxorubicin and disulfiram Polymeric micelles Breast cancer [58] Doxorubicin and curcumin Polymeric micelles Breast cancer [59] Doxorubicin and paclitaxel Pluronic mixed micelles Breast cancer [60] Docetaxel and chloroquine PEO-PPO-PCL/TPGS micelles Breast cancer [61] Paclitaxel and curcumin PEG-PE and vitamin E micelles Ovarian cancer [62] In order to eradicate ovarian cancer, Desale et al [56] synthesized biodegradable triblock copolymers containing ethylene glycol, glutamic acid, and phenylalanine (PEG-PGlu-PPhe). These copolymers self-assembled to form micelles for the co-delivery of CDDP and PTX, and the resulting nanomedicine mounted strong tumor suppression effects both in vitro and in vivo.…”

Section: Combined Chemotherapeuticsmentioning

confidence: 99%

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Chen¹,

Xie²,

Sun³

et al. 2017

PHARMSCI

View full text Add to dashboard Cite

Background:Combined chemotherapy has gradually become one of the conventional methods of cancer treatment due to the limitation of monotherapy. However, combined chemotherapy has several drawbacks that may lead to treatment failure because drug synergy cannot be guaranteed, achievement of the optimal synergistic drug ratio is difficult, and drug uptake into the tumor is inconsistent. Nanomedicine can be a safe and effective form of drug delivery, which may address the problems associated with combination chemotherapy. Objective:This review summarizes the recent research in this area, including the use of nanoparticles, liposomes, lipid-polymer hybrid nanoparticles, and polymeric micelles, and provides new approach for combined chemotherapy. Methods:By collecting and referring to the related literature in recent years. Results:Compared with conventional drugs, nanomedicine has the following advantages: it increases bioavailability of poorly soluble drugs, prolongs drug circulation time in vivo, and permits multiple drug loading, all of which could improve drug efficacy and reduce toxicity. Furthermore, nanomedicine can maintain the synergistic ratio of the drugs; deliver the drugs to the tumor at the same time, such that two or more drugs of tumor treatment achieve synchronization in time and space; and alter the pharmacokinetics and distribution profile in vivo such that these are dependent on nanocarrier properties (rather than being dependent on the drugs themselves). Conclusion:Therefore, nanomedicine-mediated combination drug therapy is promising in the treatment of tumors.

show abstract

Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer

Cited by 110 publications

References 21 publications

Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis

Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis

Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting

Nanomedicine-Mediated Combination Drug Therapy in Tumor

Contact Info

Product

Resources

About